Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Akebia Therapeutics	Viking Therapeutics	Inozyme Pharma	Kala Pharmaceuticals	Altimmune
Symbol	NASDAQ:AKBA	NASDAQ:VKTX	NASDAQ:INZY	NASDAQ:KALA	NASDAQ:ALT
Price Information
Current Price	$3.50	$6.03	$15.95	$5.41	$14.07
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.6	1.7	1.7	1.8
Analysis Score	3.3	3.6	3.5	3.4	3.5
Community Score	2.7	3.5	2.8	2.6	3.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$7.83	$16.89	$36.00	$21.33	$31.75
% Upside from Price Target	123.81% upside	180.08% upside	125.71% upside	294.33% upside	125.66% upside
Trade Information
Market Cap	$560.40 million	$470.94 million	$374.55 million	$349.71 million	$522.70 million
Beta	2.11	2.02	N/A	0.43	1.51
Average Volume	5,504,335	1,245,042	55,946	2,370,435	1,405,161
Sales & Book Value
Annual Revenue	$335 million	N/A	N/A	$6.07 million	$5.80 million
Price / Sales	1.67	N/A	N/A	57.61	90.12
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.32 per share	$3.83 per share	N/A	$0.86 per share	$2.97 per share
Price / Book	1.05	N/A	N/A	6.29	4.74
Profitability
Net Income	$-279,660,000.00	$-25,780,000.00	N/A	$-94,350,000.00	$-20,520,000.00
EPS	($1.63)	($0.36)	N/A	($2.76)	($0.98)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	24.68
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-126.86%	N/A	N/A	-1,794.36%	-659.33%
Return on Equity (ROE)	-68.51%	-13.57%	N/A	-93.73%	-46.39%
Return on Assets (ROA)	-34.01%	-13.14%	N/A	-43.09%	-38.32%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.24%	N/A	N/A	0.68%	N/A
Current Ratio	2.15%	27.08%	16.71%	9.11%	34.66%
Quick Ratio	1.67%	27.09%	16.71%	8.73%	34.66%
Ownership Information
Institutional Ownership Percentage	68.98%	54.13%	69.77%	67.63%	66.22%
Insider Ownership Percentage	2.55%	3.70%	N/A	34.15%	2.70%
Miscellaneous
Employees	379	18	38	188	43
Shares Outstanding	160.12 million	78.10 million	23.48 million	64.64 million	37.15 million
Next Earnings Date	8/9/2021 (Estimated)	8/4/2021 (Estimated)	9/2/2021 (Estimated)	8/5/2021 (Estimated)	8/10/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Altimmune (NASDAQ:ALT) Posts Earnings Results, Beats Expectations By $0.01 EPS americanbankingnews.com - May 18 at 7:24 AM
	Altimmune Inc (ALT) has risen 7.42% in a Week, Should You Sell? - InvestorsObserver investorsobserver.com - May 17 at 10:42 PM
	Altimmune awaits Covid vaccine results, preps next trials for AdCovid intranasal spray - Washington Business Journal - Washington Business Journal bizjournals.com - May 17 at 5:42 PM
	Looking Into Altimmune's Return On Capital Employed - Benzinga benzinga.com - May 17 at 2:20 PM
	Altimmune Q1 loss soars 282% as expenses rise dramatically; shares up ~3% - Seeking Alpha seekingalpha.com - May 17 at 1:45 PM
	Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update - BioSpace biospace.com - May 17 at 1:45 PM
	ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript - Motley Fool fool.com - May 17 at 12:42 PM
	Altimmune Posts Q1 Loss Per Share $0.38 - CMLViz.com - CML News cmlviz.com - May 17 at 12:42 PM
	Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance finance.yahoo.com - May 17 at 12:42 PM
	Form 10-Q Altimmune, Inc. For: Mar 31 - StreetInsider.com streetinsider.com - May 17 at 7:41 AM
	ALTIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com marketscreener.com - May 17 at 7:41 AM
	Altimmune Announces First Quarter 2021 Financial Results - GlobeNewswire globenewswire.com - May 17 at 7:41 AM
	Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update finance.yahoo.com - May 17 at 7:41 AM
	Altimmune earnings: here's what Wall Street expects markets.businessinsider.com - May 16 at 8:31 AM
	Altimmune Inc Registered Shs hosts conference call for investors markets.businessinsider.com - May 15 at 12:41 AM
	UAB: Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity In Preclinical Tests - Patch.com patch.com - May 13 at 10:40 PM
	Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Buy" from Brokerages americanbankingnews.com - May 13 at 1:38 AM
	The Altimmune (NASDAQ:ALT) Share Price Has Gained 261%, So Why Not Pay It Some Attention? - Nasdaq nasdaq.com - May 12 at 1:01 PM
	Altimmune (ALT) to Release Earnings on Monday americanbankingnews.com - May 12 at 9:52 AM
	Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily investors.com - May 11 at 3:39 PM
	Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 - Yahoo Finance finance.yahoo.com - May 11 at 1:05 PM
	Altimmune - Consensus Indicates Potential 223.5% Upside - DirectorsTalk Interviews directorstalkinterviews.com - May 11 at 9:16 AM
	Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 finance.yahoo.com - May 11 at 8:04 AM
	Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace investorplace.com - May 10 at 9:36 AM
	Thinking about buying stock in Polarityte, AMC Entertainment, Altimmune, iHeartMedia, or Vale? - PRNewswire prnewswire.com - May 10 at 9:36 AM

Date	Company	Brokerage	Action
3/15/2021	Akebia Therapeutics	HC Wainwright	Lower Price Target
3/15/2021	Akebia Therapeutics	Cantor Fitzgerald	Initiated Coverage
1/29/2021	Akebia Therapeutics	JPMorgan Chase & Co.	Downgrade
9/4/2020	Akebia Therapeutics	Morgan Stanley	Lower Price Target
9/4/2020	Akebia Therapeutics	BTIG Research	Lower Price Target
9/4/2020	Akebia Therapeutics	Mizuho	Lower Price Target
8/11/2020	Akebia Therapeutics	Needham & Company LLC	Initiated Coverage
5/6/2020	Akebia Therapeutics	Royal Bank of Canada	Boost Price Target
5/3/2021	Viking Therapeutics	SVB Leerink	Reiterated Rating
1/22/2021	Viking Therapeutics	Stifel Nicolaus	Reiterated Rating
10/29/2020	Viking Therapeutics	Raymond James	Boost Price Target
9/11/2020	Viking Therapeutics	William Blair	Reiterated Rating
9/10/2020	Viking Therapeutics	B. Riley	Reiterated Rating
8/31/2020	Viking Therapeutics	Chardan Capital	Boost Price Target
7/29/2020	Viking Therapeutics	Oppenheimer	Reiterated Rating
6/4/2020	Viking Therapeutics	BMO Capital Markets	Initiated Coverage
5/2/2020	Viking Therapeutics	Maxim Group	Initiated Coverage
8/18/2020	Inozyme Pharma	Wedbush	Initiated Coverage
8/18/2020	Inozyme Pharma	Bank of America	Initiated Coverage
8/18/2020	Inozyme Pharma	Piper Sandler	Initiated Coverage
8/18/2020	Inozyme Pharma	Cowen	Initiated Coverage
11/30/2020	Kala Pharmaceuticals	Northland Securities	Reiterated Rating
9/14/2020	Kala Pharmaceuticals	Jefferies Financial Group	Downgrade
2/10/2021	Altimmune	Guggenheim	Initiated Coverage
11/24/2020	Altimmune	Evercore ISI	Reiterated Rating
7/28/2020	Altimmune	JMP Securities	Initiated Coverage
2/24/2020	Altimmune	Roth Capital	Initiated Coverage
5/29/2018	Altimmune	Dawson James	Reiterated Rating

(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources